Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human Imaging With 89Zr-DFO-pertuzumab in Patients With HER2 Positive Malignancies

NCT03109977 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT03109977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03109977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human Imaging With 89Zr-DFO-pertuzumab in Patients With HER2 Positive Malignancies
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2017
Completion date
April 12, 2018
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive carcinoma, her2-positive primary malignancy